Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Shionogi to Transfer Manufacturing Functions to Dedicated Unit
April 24, 2018
- Eisai Transfers European Prialt Rights to Riemser
April 24, 2018
- Top Court Favors Sandoz in Elplat Patent Suit
April 24, 2018
- Atozet, Zetia-Lipitor Combo, Now Available in Japan after Delay
April 24, 2018
- Dupixent Hits Japan Shelves: Sanofi
April 24, 2018
- Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
- Japan Ethical Drug Sales in 54 Fields Shrink 1.6% in 2017
April 23, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup
April 19, 2018
- Astellas Sells Agensys Research Facilities to Kite
April 19, 2018
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit
April 19, 2018
- FDA Clears Kyowa Kirin/Ultragenyx’s XLH Drug Burosumab
April 19, 2018
- Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
- PeptiStar’s Funding Procurement Nears 20 Billion Yen
April 19, 2018
- Former GSK Japan Chief Kanako Kikuchi Named UCB Japan President
April 19, 2018
- Pharmbio Korea Gets Rights to Shionogi’s Ospemifene
April 18, 2018
- Another Huge Seller Re-Pricing Won’t Hit Opdivo Unless 195 Billion Yen Sales Reached: Ono Chief
April 18, 2018
- Sumitomo Dainippon Reorganizes Drug Discovery Research System; Accelerating Decision-Making: Pres.
April 18, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…